Copyright
©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.104827
Table 1 Detailed characteristics of patients recruited in the study
Characteristic | Details | Concomitant medications |
Total number of patients | 10 | |
Gender | 6 females, 4 males | |
Mean age | 65 years | |
Age range | 50-80 years | |
Cancer types | Lung cancer: 4 patients (40%) | Cisplatin; Paclitaxel; Ondansetron; Dexamethasone; Diclofenac |
Breast cancer: 3 patients (30%) | Doxorubicin; Cyclophosphamide; Zolendronic acid; Letrozole;Anastrozole; Dexamethasone; Diclofenac | |
Prostate cancer: 2 patients (20%) | Leuprolide; Enzalutamide; Zolendronic acid; Diclofenac | |
Pancreatic cancer: 1 patient (10%) | Gemcitabine; 5-Fluorouracil; Dexamethasone; Diclofenac |
- Citation: Chakraborty P, Borgohain M. Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series. World J Clin Oncol 2025; 16(4): 104827
- URL: https://www.wjgnet.com/2218-4333/full/v16/i4/104827.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i4.104827